Rivoglitazone

Rivoglitazone
Systematic (IUPAC) name
	(RS)-5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
Identifiers
CAS Number	185428-18-6
ATC code	none
PubChem	CID: 3055168
ChemSpider	2316729
UNII	3A3N0634Q6
ChEMBL	CHEMBL2104753
Chemical data
Formula	C20H19N3O4S
Molecular mass	397.448 g/mol
	SMILES CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4 ;
	InChI InChI=1S/C20H19N3O4S/c1-23-16-10-14(26-2)7-8-15(16)21-18(23)11-27-13-5-3-12(4-6-13)9-17-19(24)22-20(25)28-17/h3-8,10,17H,9,11H2,1-2H3,(H,22,24,25) ; Key:XMSXOLDPMGMWTH-UHFFFAOYSA-N ;
(verify)

Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.^[1]^[2]

It is being developed by Daiichi Sankyo.

References

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.